CN1989138A - 可用于治疗增殖性疾病的2－取代的－4－杂芳基－嘧啶类 - Google Patents

可用于治疗增殖性疾病的2－取代的－4－杂芳基－嘧啶类 Download PDF

Info

Publication number
CN1989138A
CN1989138A CNA2005800241399A CN200580024139A CN1989138A CN 1989138 A CN1989138 A CN 1989138A CN A2005800241399 A CNA2005800241399 A CN A2005800241399A CN 200580024139 A CN200580024139 A CN 200580024139A CN 1989138 A CN1989138 A CN 1989138A
Authority
CN
China
Prior art keywords
methyl
thiazol
pyrimidin
phenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800241399A
Other languages
English (en)
Chinese (zh)
Inventor
王淑东
加文·伍德
肯尼思·邓肯
克里斯托弗·米德斯
达龙·吉布森
贾尼丝·麦克拉克伦
彼得·费希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of CN1989138A publication Critical patent/CN1989138A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
CNA2005800241399A 2004-05-26 2005-05-26 可用于治疗增殖性疾病的2－取代的－4－杂芳基－嘧啶类 Pending CN1989138A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411791.7 2004-05-26
GBGB0411791.7A GB0411791D0 (en) 2004-05-26 2004-05-26 Compounds

Publications (1)

Publication Number Publication Date
CN1989138A true CN1989138A (zh) 2007-06-27

Family

ID=32671118

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800241399A Pending CN1989138A (zh) 2004-05-26 2005-05-26 可用于治疗增殖性疾病的2－取代的－4－杂芳基－嘧啶类

Country Status (11)

Country Link
US (1) US20090137572A1 (enExample)
EP (1) EP1756098A2 (enExample)
JP (1) JP5026259B2 (enExample)
CN (1) CN1989138A (enExample)
AU (1) AU2005247682A1 (enExample)
BR (1) BRPI0511616A (enExample)
CA (1) CA2566051A1 (enExample)
GB (1) GB0411791D0 (enExample)
IL (1) IL179508A0 (enExample)
MX (1) MXPA06013632A (enExample)
WO (1) WO2005116025A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180870A (zh) * 2010-10-21 2011-09-14 浙江医药高等专科学校 {4-[2-(芳基-甲基胺)-4-甲基-噻唑-5]-嘧啶-2}-芳胺衍生物、制备方法及所述衍生物的制药用途
CN101203500B (zh) * 2005-01-25 2013-08-21 格利尼公司 取代的芳胺化合物和它们作为5-ht6调节剂的用途
CN103403002A (zh) * 2011-02-24 2013-11-20 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
CN102180870B (zh) * 2010-10-21 2016-12-14 浙江医药高等专科学校 {4‑[2‑(芳基‑甲基胺)‑4‑甲基‑噻唑‑5]‑嘧啶‑2}‑芳胺衍生物、制备方法及所述衍生物的制药用途
CN111039941A (zh) * 2018-10-12 2020-04-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
CN111757881A (zh) * 2018-01-15 2020-10-09 澳升控股有限公司 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
WO2025011447A1 (zh) * 2023-07-13 2025-01-16 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
RU2007119637A (ru) * 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
JP5186219B2 (ja) 2005-01-25 2013-04-17 エピックス デラウェア， インコーポレイテッド 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
EP2197876A1 (en) * 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
AU2008309517B2 (en) * 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
JP2011506454A (ja) * 2007-12-13 2011-03-03 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
JP6106685B2 (ja) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
MX358346B (es) * 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN113336746A (zh) * 2015-08-04 2021-09-03 常州千红生化制药股份有限公司 N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
IL325253A (en) * 2023-06-14 2026-02-01 Prothena Biosciences Ltd 5-(Cinnoline-6-yl)thiazole compounds for the treatment of neurological disorders
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE69736351T4 (de) * 1996-05-08 2009-07-23 Cyclacel Ltd. Methoden und mittel zur hemmung der cdk4-aktivität
AU753015B2 (en) * 1998-03-04 2002-10-03 Cyclacel Limited Cyclin dependent kinase inhibitor
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
DE69919707T2 (de) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB2361236B (en) * 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
WO2002096905A1 (en) * 2001-06-01 2002-12-05 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
CA2460909A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
JP2006524688A (ja) * 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
JP2007500178A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
EP1648875A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
BRPI0415759A (pt) * 2003-10-21 2006-12-19 Cyclacel Ltd compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
WO2005113550A1 (ja) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation アミノピリミジン誘導体及びその医薬としての用途

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203500B (zh) * 2005-01-25 2013-08-21 格利尼公司 取代的芳胺化合物和它们作为5-ht6调节剂的用途
CN102180870A (zh) * 2010-10-21 2011-09-14 浙江医药高等专科学校 {4-[2-(芳基-甲基胺)-4-甲基-噻唑-5]-嘧啶-2}-芳胺衍生物、制备方法及所述衍生物的制药用途
CN102180870B (zh) * 2010-10-21 2016-12-14 浙江医药高等专科学校 {4‑[2‑(芳基‑甲基胺)‑4‑甲基‑噻唑‑5]‑嘧啶‑2}‑芳胺衍生物、制备方法及所述衍生物的制药用途
CN103403002A (zh) * 2011-02-24 2013-11-20 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
CN103403002B (zh) * 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
CN111757881A (zh) * 2018-01-15 2020-10-09 澳升控股有限公司 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
CN111757881B (zh) * 2018-01-15 2024-05-07 澳升医药公司 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
CN111039941A (zh) * 2018-10-12 2020-04-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
CN111039941B (zh) * 2018-10-12 2023-03-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
WO2025011447A1 (zh) * 2023-07-13 2025-01-16 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
AU2005247682A1 (en) 2005-12-08
EP1756098A2 (en) 2007-02-28
WO2005116025A3 (en) 2006-02-23
GB0411791D0 (en) 2004-06-30
WO2005116025A2 (en) 2005-12-08
MXPA06013632A (es) 2007-03-23
JP5026259B2 (ja) 2012-09-12
IL179508A0 (en) 2007-05-15
BRPI0511616A (pt) 2008-01-02
CA2566051A1 (en) 2005-12-08
US20090137572A1 (en) 2009-05-28
JP2008500320A (ja) 2008-01-10

Similar Documents

Publication Publication Date Title
CN100415740C (zh) 嘧啶化合物
JP5026259B2 (ja) 増殖性障害の治療に有用な２−置換−４−ヘテロアリール−ピリミジン
US10351578B2 (en) Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof
JP5164380B2 (ja) ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
US20100331315A1 (en) Rhodanines and related heterocycles as kinase inhibitors
CN101111490A (zh) 4-(1h-吲哚-3-基)-嘧啶-2-基胺衍生物及其治疗用途
AU2013366513B2 (en) Novel benzimidazole derivatives as kinase inhibitors
CN102143953B (zh) 嘧啶、三嗪类化合物以及它们作为药剂的用途
CN102458412A (zh) 作为激酶抑制剂的吡唑并嘧啶和相关杂环
KR20070095978A (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
EP2209779A1 (en) Heterocyclic urea and thiourea derivatives and methods of use thereof
MXPA04010474A (es) Piperazinbenzotiazoles como agentes para el tratamiento de trastornos isquemicos cerebrales o trastornos del sistema nerviosos central.
McIntyre et al. Design, synthesis, and evaluation of 2-methyl-and 2-amino-N-aryl-4, 5-dihydrothiazolo [4, 5-h] quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl) pyrimidine cyclin-dependent kinase inhibitors
CN1976910B (zh) 2,4-二氨基噻唑-5-酮衍生物
CN103524442A (zh) 嘧啶化合物，三嗪类化合物及其作为药物的应用
CN1898237B (zh) 嘧啶-4-基-3,4-硫酮化合物及其治疗用途
CN106336412A (zh) 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070627